Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cervical Cancer

Cervical Cancer

34 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cervical Cancer

163 trials tracked for Cervical Cancer: 32 in phase 3 or 4 and 15 with published results. The most-cited published study has 1520 citations.

163Trials tracked
32Phase 3 & 4
0Recruiting
15With published results
Phase distribution
Phase 4 5 Phase 3 27 Phase 2 63 Phase 1 14 Other / NA 54
  1. Phase 3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed · 1,520 cited
  2. Phase 3 Study of Cemiplimab in Adults With Cervical Cancer Completed · 441 cited
  3. Phase 3 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) Completed · 387 cited
  4. Phase 3 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Completed · 372 cited
  5. Phase 3 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Completed · 259 cited
  6. Phase 3 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Completed · 200 cited
Show 44 more trials
  1. Phase 3 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Completed · 183 cited
  2. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 113 cited
  3. Phase 3 Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Completed · 42 cited
  4. Phase 3 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Completed · 41 cited
  5. Phase 3 Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls Completed · 23 cited
  6. Phase 3 Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial Completed · 9 cited
  7. Phase 4 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed · 8 cited
  8. Phase 3 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) Completed · 4 cited
  9. Phase 3 Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) Completed · 4 cited
  10. Phase 4 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Completed
  11. Phase 4 Alternate Dosing Schedules Study for HPV Vaccine Completed
  12. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  13. Phase 3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed
  14. Phase 3 Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer Completed
  15. Phase 3 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Completed
  16. Phase 3 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Completed
  17. Phase 3 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Completed
  18. Phase 3 Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer Completed
  19. Phase 3 A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Completed
  20. Phase 3 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed
  21. Phase 3 Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) Completed
  22. Phase 3 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) Completed
  23. Phase 3 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed
  24. Phase 3 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed
  25. Phase 3 Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants Completed
  26. Phase 3 Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix Completed
  27. Phase 2 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Completed
  28. Phase 2 A Study of Patients Receiving High-Dose Rate Brachytherapy Completed
  29. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  30. Phase 2 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed
  31. Phase 2 Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer Completed
  32. Phase 2 Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy Completed
  33. Phase 2 Irinotecan Study For Cervical Cancer Completed
  34. Phase 2 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed
  35. Phase 2 Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer Completed
  36. Phase 2 Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium Completed
  37. Phase 2 Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer Completed
  38. Phase 2 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer Completed
  39. Phase 2 Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix Completed
  40. Phase 2 Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers Completed
  41. Phase 2 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
  42. Phase 2 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive Completed
  43. Phase 2 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed
  44. Phase 2 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers Completed

Showing the 50 most-cited and recently-updated of 163 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Cervical Cancer: what the trials found

Pembrolizumab has demonstrated significant improvements in progression-free survival (PFS) for cervical cancer patients. In one study, PFS was significantly higher compared to the control group as assessed by both investigator and blinded independent central review (BICR) 1. Another trial confirmed superior outcomes for Pembrolizumab across various cohorts, including those with a Programmed Cell Death-Ligand 1 (PD-L1) combined positive score (CPS) of ≥1 or ≥10 11.

Cemiplimab showed statistically significant improvements in both overall survival (OS) and progression-free survival (PFS) compared to standard treatments, with notable benefits observed specifically within the squamous cell carcinoma (SCC) population 9. Tisotumab vedotin also demonstrated superior OS, PFS, and confirmed objective response rates (ORR) compared to alternative therapies 13.

Several vaccines have been evaluated for cervical cancer prevention. Quadrivalent HPV vaccines (types 6, 11, 16, and 18) were shown to produce high seropositivity for types 16 and 18 at 36 months 17, while the 9vHPV vaccine achieved 100% seroconversion across multiple HPV types by month 7 19. Other vaccines including V501 [4, 18] and V503 15 demonstrated high geometric mean titers (GMTs) for anti-HPV antibodies.

Chemotherapeutic agents such as Carboplatin [12, 21] and Cisplatin [14, 20] are established in the treatment landscape. Additionally, standard radiation therapy was evaluated regarding toxicity; while some differences were noted in acute gastrointestinal and urinary toxicity scores, the percentage of patients with high-grade GI toxicity did not differ significantly from controls 10.

Recent results — preliminary, needs further review

  • TA-CIN (arm) is currently under investigation in a Phase 1 trial 2.

For the clinician treating this condition

  • Pembrolizumab and Cemiplimab are supported by evidence showing significant improvements in progression-free survival and overall survival [1, 9, 11].
  • Tisotumab vedotin is associated with superior objective response rates and progression-free survival compared to standard treatments 13.
  • Multiple HPV vaccines (including quadrivalent and 9vHPV) demonstrate high seroconversion and immunogenicity against major oncogenic types [17, 19].

AI synthesis of 9 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Self-collected HPV tests detect 81% to 88.6% of high-grade cervical lesions
Oncology Meta-analysis
Self-collected HPV tests detect 81% to 88.6% of high-grade cervical lesions Self-collected HPV tests detect most cervical cancer cases
This meta-analysis assessed the diagnostic accuracy of HPV testing using self-collected urine and vaginal specimens for detecting high-grade…
Self-collected urine and vaginal samples catch most high-grade cervical lesions, making screening easier and more private.
Aug 6, 2026
Immune checkpoint inhibitors show higher rates of high-grade immune-related adverse events in cervical cancer
OB/GYN & Women's Health Meta-analysis
Immune checkpoint inhibitors show higher rates of high-grade immune-related adverse events in cervical cancer Immune checkpoint inhibitors show specific safety risks in cervical cancer
This meta-analysis of 3302 patients with cervical cancer evaluated the safety profile of immune checkpoint inhibitors (ICIs) compared to sta…
New analysis shows that while some side effects of immune checkpoint inhibitors are similar to standard care, certain high grade immune reac…
Aug 2, 2026
Cervical cancer patients face mean treatment delays of 71.42 days from histopathological diagnosis
OB/GYN & Women's Health Meta-analysis
Cervical cancer patients face mean treatment delays of 71.42 days from histopathological diagnosis Cervical cancer treatment delays average 71 days
This meta-analysis evaluates the time elapsed between histopathological diagnosis and first-line definitive treatment for cervical cancer. T…
A global review finds cervical cancer patients wait about 71 days for treatment, with longer delays in middle-income countries.
Aug 2, 2026
DNA Methylation Tests Show High Accuracy for Cervical Cancer Triage
Oncology Meta-analysis
DNA Methylation Tests Show High Accuracy for Cervical Cancer Triage DNA methylation tests show promise for identifying high grade cervical cell changes
Meta-analysis of 28,977 HPV+ women finds DNA methylation markers like JAM3 and PAX1 have high diagnostic odds ratios for detecting CIN2+.
New tests looking at DNA markers can help doctors find serious cervical cell changes more accurately than some current methods.
Jul 26, 2026
Intimate partner violence triples cervical cancer risk in meta-analysis of adult women
Oncology Meta-analysis
Intimate partner violence triples cervical cancer risk in meta-analysis of adult women Intimate partner violence linked to higher risk of cervical cancer
This systematic review and meta-analysis found that intimate partner violence (IPV) exposure is associated with a 3-fold increased odds of c…
Women who have experienced intimate partner violence face a significantly higher risk of developing cervical cancer.
medRxiv Jul 17, 2026
27 facilitators and 79 barriers shape cervical cancer screening in women living with HIV
Primary Care & Family Medicine Meta-analysis
27 facilitators and 79 barriers shape cervical cancer screening in women living with HIV Identifying barriers to cervical cancer screening for women with HIV
This meta-aggregative synthesis of 10 qualitative studies identifies 27 facilitators and 79 barriers to cervical cancer screening among wome…
Women living with HIV face significant hurdles when trying to access cervical cancer screenings. New research identifies the specific obstac…
Frontiers Jul 3, 2026
NLRP3 inflammasome modulates immune evasion and chemotherapy sensitivity in gynecological cancers
Allergy & Immunology Sys. Review
NLRP3 inflammasome modulates immune evasion and chemotherapy sensitivity in gynecological cancers New research identifies a key driver in gynecological cancer cells
This mini-review examines the role of the NLRP3 inflammasome in ovarian, endometrial, and cervical cancers. It highlights how NLRP3 impacts …
A protein called NLRP3 helps certain cancers hide from the immune system, but it also plays a complex role in how tumors react to treatment.
Frontiers Jun 24, 2026
Low pretreatment lymphocyte-to-monocyte ratio linked to worse survival in cervical cancer
Oncology Meta-analysis
Low pretreatment lymphocyte-to-monocyte ratio linked to worse survival in cervical cancer Low LMR Linked to Worse Survival in Cervical Cancer Patients
This systematic review and meta-analysis of 5,127 patients found that low pretreatment lymphocyte-to-monocyte ratio (LMR) is associated with…
A low lymphocyte-to-monocyte ratio before treatment predicts poorer survival outcomes for patients with cervical cancer, suggesting a potent…
Jun 6, 2026
Adjuvant radiotherapy improves recurrence-free survival for intermediate-risk cervical cancer patients after surgery
OB/GYN & Women's Health Meta-analysis
Adjuvant radiotherapy improves recurrence-free survival for intermediate-risk cervical cancer patients after surgery Adjuvant radiotherapy improves recurrence-free survival for early-stage cervical cancer patients
A large meta-analysis of 9,278 patients confirms adjuvant radiotherapy significantly reduces recurrence compared to no further treatment. Co…
A large analysis of nearly 9,300 patients found that adding radiotherapy after surgery reduces the risk of cancer returning without increasi…
Jun 1, 2026
FAPI PET shows higher sensitivity and specificity than FDG for cervical cancer diagnosis
OB/GYN & Women's Health Meta-analysis
FAPI PET shows higher sensitivity and specificity than FDG for cervical cancer diagnosis New imaging scan finds cervical cancer better than the standard test
This systematic review and meta-analysis of 109 patients found that fibroblast activation protein inhibitor (FAPI) PET had higher sensitivit…
A new analysis shows a specific scan finds cervical cancer more often than the standard test, helping doctors see the disease earlier in pat…
Jun 1, 2026
Meta-analysis shows immune checkpoint inhibitor combinations improve survival and response rates in advanced cervical cancer patients with manageable safety profiles
Oncology Meta-analysis
Meta-analysis shows immune checkpoint inhibitor combinations improve survival and response rates in advanced cervical cancer patients with manageable safety profiles ICI Combinations Improve Survival for Advanced Cervical Cancer
This systematic review analyzed 4,441 patients with advanced cervical cancer to evaluate immune checkpoint inhibitor combinations. Results i…
Combining immune checkpoint inhibitors with other treatments significantly improved survival and disease control for patients with advanced …
Frontiers May 25, 2026
Bowel Dose-Volume Predictors of GI Toxicity in Postoperative Radiotherapy for Cervical Cancer
OB/GYN & Women's Health RCT
Bowel Dose-Volume Predictors of GI Toxicity in Postoperative Radiotherapy for Cervical Cancer Bowel radiation doses linked to GI side effects in cervical cancer
This phase III RCT (PARCER trial) in 283 patients with cervical cancer found that bowel V30Gy and V40Gy were associated with acute and late …
Higher radiation doses to the bowel increase gastrointestinal toxicity risk in cervical cancer patients. IMRT reduces this risk compared to …
May 3, 2026

Questions about Cervical Cancer

How does innate immune recognition affect the progression of Cervical Cancer and HPV?

HPV evades innate immune detection by suppressing PRR signaling and NLRP3 inflammasome, enabling persistent infection and cervical cancer progression.

Full answer →